Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia

Inclusion Criteria:

* Ability to understand and the willingness to sign a written informed consent document
* Eastern Cooperative Oncology Group (ECOG) performance status =\< 2
* Newly diagnosed AML as confirmed by bone marrow and/or peripheral blood examination as indicated, with:

  * Confirmed CD33 positivity, per institutional standards
  * Presence of FLT3 internal tandem duplication (ITD) or tyrosine kinase domain (TKD) mutation as confirmed by next-generation sequencing (NGS) or other molecular method
* Aspartate aminotransferase (AST) \< 2.5 x upper limit of normal (ULN; local laboratory)
* Alanine aminotransferase (ALT) \< 2.5 x ULN
* Total bilirubin \< 2 x ULN (except for patients with known Gilbert's syndrome)
* Calculated creatinine clearance (according to the Cockcroft-Gault equation) \> 40 mL/min OR serum creatinine \< 1.5 x the ULN
* Female patients of childbearing potential must agree to use adequate contraception (2 forms of contraception or abstinence) from the screening visit until 6 months following the last dose of study treatment. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
* Male patients of childbearing potential having intercourse with females of childbearing potential must agree to abstain from heterosexual intercourse or have their partner use 2 forms of contraception from the screening visit until 4 months following the last dose of study treatment. They must also refrain from sperm donation from the screening visit until 4 months following the last dose of study treatment

Exclusion Criteria:

* Isolated myeloid sarcoma (meaning, patients must have blood or marrow involvement to enter study)
* Acute promyelocytic leukemia (per World Health Organization classification)
* Active central nervous system (CNS) involvement by AML, as assessed at discretion of principal investigator (PI) or treating physician and confirmed by lumbar puncture
* Except for hydroxyurea, no other prior systemic anti-AML therapies may have been received prior to starting study therapy
* Known history of veno-occlusive disease
* Known active human immunodeficiency virus (HIV), active hepatitis B or active hepatitis C infection
* Patients with the following will be excluded: uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, serious cardiac arrhythmia, myocardial infarction within 6 months prior to enrollment, New York Heart Association (NYHA) class III or IV heart failure, severe uncontrolled ventricular arrhythmias
* Patients with uncontrolled infection will not be enrolled until infection is treated
* Any concurrent condition that, in the investigator's opinion, would jeopardize the safety of the patient or compliance with the protocol
* Inability to take oral medication
* Hypersensitivity to any study agent, or its excipients, when administered alone
* Pregnancy or breastfeeding at the time of enrollment